Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$67.33

1.98 (3.03%)

, CRM

Salesforce

$111.85

2.83 (2.60%)

10:20
02/15/18
02/15
10:20
02/15/18
10:20

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying he has become more optimistic on the immuno-oncology Opdivo + Yervoy combo in first-line lung cancer, which he notes is the largest cancer market. 2. Salesforce (CRM) upgraded to Buy from Hold at Jefferies with analyst John DiFucci saying recent field checks indicate continued strong enterprise traction as well improved commercial segment momentum, likely due to moderating Microsoft (MSFT) competition. 3. Credit Suisse (CS) upgraded to Buy from Hold at Societe Generale. 4. FMC Corporation (FMC) upgraded to Buy from Neutral at Seaport Global with analyst Michael Harrison saying he sees near-term catalysts from the Ag market recovery and secular growth in lithium, which the company plans to spinoff. 5. Baidu (BIDU) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Grace Chen citing expectations for search sales reacceleration in 2018, the potential catalyst of the iQiyi IPO and the long-term potential contributions from AI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

BMY

Bristol-Myers

$67.33

1.98 (3.03%)

CRM

Salesforce

$111.85

2.83 (2.60%)

CS

Credit Suisse

$18.66

0.0001 (0.00%)

FMC

FMC Corporation

$85.89

0.63 (0.74%)

BIDU

Baidu

$235.89

10.29 (4.56%)

  • 15

    Feb

  • 20

    Feb

  • 21

    Feb

  • 26

    Feb

  • 28

    Feb

  • 01

    Mar

  • 05

    Mar

  • 08

    Mar

  • 19

    Mar

  • 24

    Apr

BMY Bristol-Myers
$67.33

1.98 (3.03%)

02/15/18
02/15/18
UPGRADE
Target $78

Overweight
Bristol-Myers upgraded on immuno-oncology growth prospects at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Bristol-Myers (BMY) to Overweight from Equal Weight as he has become more optimistic on the immuno-oncology Opdivo + Yervoy combo in first-line lung cancer, which he notes is the largest cancer market. After the analyst reviewed combo toxicity in select combo studies with similar dosing as Bristol's CM-227 and compared cross trial against Merck's (MRK) Keynote-021G trial that tested Keytruda + chemo, he concluded that discontinuation rates due to side effects appear roughly comparable and now thinks Opdivo + Yervoy toxicity in lung cancer is likely to be acceptable. Risinger raised his price target on Bristol-Myers shares to $78 from $63.
02/14/18
JEFF
02/14/18
NO CHANGE
Target $88
JEFF
Buy
Nektar takeover not off table with Bristol deal, says Jefferies
Jefferies analyst David Steinberg finds it important that Nektar Therapeutics (NKTR) retains ownership of NKTR-214 following its collaboration with Bristol-Myers (BMY) and that it can continue to collaborate with other companies. Further, the potential to be acquired is not off the table, Steinberg tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $88 price target.
02/15/18
MSCO
02/15/18
UPGRADE
MSCO
Overweight
Bristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
02/15/18
SBSH
02/15/18
NO CHANGE
Target $62
SBSH
Neutral
Alkermes catalysts are the major focus this year, says Citi
Citi analyst Liav Abraham says that while Alkermes' (ALKS) fiscal 2018 revenue outlook came in below expectations, catalysts are the "major force this year." The analyst expects data from two of the company's pivotal programs and clarity around the regulatory pathway for ALKS 5461. Further, the strategic value of ALKS 4230 "can also not be discounted," following the collaboration between Bristol-Myers (BMY) and Nektar Therapeutics (NKTR), Abraham tells investors in a post-earnings research note. ALKS 4230, an IL-2 inhibitor, gives Alkermes optionality as it is not an "obvious" fit into the company's psychiatry-oriented portfolio, the analyst contends. She keeps a Neutral rating on Alkermes with a $62 price target.
CRM Salesforce
$111.85

2.83 (2.60%)

01/31/18
01/31/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lumentum (LITE) was initiated with a Buy at UBS while Oclaro (OCLR) was initiated with a Sell. 2. ImmunoGen (IMGN) initiated with a Buy at H.C. Wainwright. 3. Salesforce (CRM) and Workday (WDAY) were initiated with a Buy at Cleveland Research. 4. Cooper Tire (CTB) was initiated with a Buy at Longbow, while Goodyear Tire (GT) was initiated with a Neutral. 5. Acacia Communications (ACIA) initiated with a Buy at UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/06/18
UBSW
02/06/18
NO CHANGE
Target $135
UBSW
Buy
Salesforce share price undervalues growth and free cash flow, says UBS
UBS analyst Jennifer Lowe noted Salesforce bears point to the company's investments as a headwind to long-term profits, but she believes the company can drive margins above Street expectations while maintaining its greater than 20% growth. The analyst feels the stock price undervalues the company's growth and free cash flow margin expansion potential. Lowe reiterated her Buy rating and $135 price target on Salesforce shares.
02/15/18
JEFF
02/15/18
UPGRADE
Target $132
JEFF
Buy
Salesforce upgraded to Buy from Hold at Jefferies
Jefferies analyst John DiFucci upgraded Salesforce (CRM) to Buy and raised his price target for the shares to $132 from $97. Recent field checks indicate continued strong enterprise traction as well improved commercial segment momentum, likely due to moderating Microsoft (MSFT) competition, DiFucci tells investors in a research note. The analyst sees "meaningful" billings upside in Q4 and "many engines of growth" to Salesforce achieving its long-term targets. He views the valuation as reasonable at current share levels.
02/02/18
DADA
02/02/18
INITIATION
Target $28
DADA
Neutral
PROS initiated with a Neutral at DA Davidson
DA Davidson analyst Rishi Jaluria initiated PROS with a Neutral rating and a price target of $28, saying the company is amid a cloud transition since mid-2015. Jaluria likes PROS' leadership in pricing optimization for airlines, with about 60% of airlines as its customers, as well as the company's momentum in cloud transition with 95% of new deals as cloud deals in the past few quarters. The analyst is concerned about the company's cash burn however, as PROS faces "Configure Price Quote" business competition from salesforce.com (CRM) and SAP (SAP).
CS Credit Suisse
$18.66

0.0001 (0.00%)

01/16/18
LEHM
01/16/18
INITIATION
LEHM
Underweight
Credit Suisse initiated with an Underweight at Barclays
Barclays analyst Amit Goel started Credit Suisse with an Underweight rating and CHF 15.4 price target. The analyst thinks the company's new targets for 2019 and 2020 will not be achieved, along with some of the targets for 2018. He sees 16% downside potential from current share levels.
01/16/18
01/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Axalta Coating (AXTA) resumed with an Underperform at BofA/Merrill. 2. UBS (UBS) and Credit Suisse (CS) were initiated with an Underweight at Barclays. 3. Nutrien (NTR) initiated with a Neutral at Goldman Sachs. 4. Cambrex (CBM) initiated with an Outperform at William Blair. 5. Dicerna (DRNA) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/15/18
SOCG
02/15/18
UPGRADE
SOCG
Buy
Credit Suisse upgraded to Buy from Hold at Societe Generale
01/09/18
SOCG
01/09/18
DOWNGRADE
Target $18.5
SOCG
Hold
Credit Suisse downgraded to Hold from Buy at Societe Generale
Societe Generale analyst Andrew Lim downgraded Credit Suisse to Hold saying the stock is now fairly priced following the recent rally. The analyst keeps an $18.50 price target for the shares.
FMC FMC Corporation
$85.89

0.63 (0.74%)

02/14/18
SBSH
02/14/18
UPGRADE
Target $95
SBSH
Buy
FMC Corporation upgraded to Buy from Neutral at Citi
Citi analyst Daniel Jester upgraded FMC Corporation to Buy while lowering his price target for the shares to $95 from $103. The recent selloff in the shares offers a "great opportunity to own a high-quality company" which is seeing stronger growth in its core Ag chemicals business, Jester tells investors in a research note. The analyst believes FMC has favorable low-cost assets and hydroxide technology.
02/14/18
FBCO
02/14/18
NO CHANGE
Target $106
FBCO
Outperform
FMC Corporation price target lowered to $106 from $111 at Credit Suisse
Credit Suisse analyst Christopher Parkinson lowered his price target for FMC Corporation to $106 from $111 to reflect a slightly lower multiple due to a reduction of core peers' valuations. The analyst believes the company is well set to execute in 2018 despite noisy market background. He reiterates an Outperform rating on the shares.
02/15/18
GHSC
02/15/18
UPGRADE
GHSC
Buy
FMC Corporation upgraded to Buy from Neutral at Seaport Global
02/15/18
02/15/18
UPGRADE
Target $105

Buy
FMC Corporation upgraded to Buy on improving outlook at Seaport Global
As previously reported, Seaport Global upgraded FMC Corporation to Buy from Neutral and increased its price target to $105 from $95 following the solid quarter and outlook. Analyst Michael Harrison sees near-term catalysts from the Ag market recovery and secular growth in lithium, which the company plans to spinoff. He expects the remaining Ag business to have significant synergy capture opportunity in terms of costs and revenues, driving growth momentum.
BIDU Baidu
$235.89

10.29 (4.56%)

02/15/18
02/15/18
UPGRADE
Target $280

Overweight
Baidu upgraded on expected search growth reacceleration at Morgan Stanley
As previously reported, Morgan Stanley analyst Grace Chen upgraded Baidu to Overweight from Equal Weight, citing expectations for search sales reacceleration in 2018, the potential catalyst of the iQiyi IPO and the long-term potential contributions from AI. After the company's recent Q4 beat and Q1 revenue guidance, Chen raised her price target on Baidu to $280 from $240.
02/14/18
MSCO
02/14/18
UPGRADE
MSCO
Overweight
Baidu upgraded to Overweight from Equal Weight at Morgan Stanley
02/14/18
DAIW
02/14/18
UPGRADE
DAIW
Outperform
Baidu upgraded to Outperform from Hold at Daiwa
02/14/18
WELS
02/14/18
NO CHANGE
Target $300
WELS
Outperform
Baidu price target raised to $300 from $290 at Wells Fargo
Wells Fargo analyst Ken Sena raised his price target for Baidu to $300 from $290 following quarterly results. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

BECN

Beacon Roofing

$31.84

-0.22 (-0.69%)

07:24
12/14/18
12/14
07:24
12/14/18
07:24
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REG

Regency Centers

$62.26

0.06 (0.10%)

07:24
12/14/18
12/14
07:24
12/14/18
07:24
Downgrade
Regency Centers rating change  »

Regency Centers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

DRGDF

Detour Gold

$0.00

(0.00%)

07:19
12/14/18
12/14
07:19
12/14/18
07:19
Downgrade
Detour Gold rating change  »

Detour Gold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$186.53

2.99 (1.63%)

, YUM

Yum! Brands

$93.49

3.02 (3.34%)

07:19
12/14/18
12/14
07:19
12/14/18
07:19
Recommendations
McDonald's, Yum! Brands analyst commentary  »

JPMorgan calls…

MCD

McDonald's

$186.53

2.99 (1.63%)

YUM

Yum! Brands

$93.49

3.02 (3.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NNN

National Retail Properties

$50.86

0.94 (1.88%)

07:18
12/14/18
12/14
07:18
12/14/18
07:18
Downgrade
National Retail Properties rating change  »

National Retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRGDF

Detour Gold

$0.00

(0.00%)

07:16
12/14/18
12/14
07:16
12/14/18
07:16
Downgrade
Detour Gold rating change  »

Detour Gold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$3.60

-0.155 (-4.13%)

07:15
12/14/18
12/14
07:15
12/14/18
07:15
Hot Stocks
Bellicum Pharmaceuticals reports data from BPX-601 at ESMO-IO »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THG

Hanover Insurance

$109.52

-0.68 (-0.62%)

07:14
12/14/18
12/14
07:14
12/14/18
07:14
Conference/Events
Hanover Insurance management to meet with Buckingham »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 19

    Dec

BHC

Bausch Health

$23.65

-0.47 (-1.95%)

07:12
12/14/18
12/14
07:12
12/14/18
07:12
Upgrade
Bausch Health rating change  »

Bausch Health upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 25

    Feb

IDRA

Idera Pharmaceuticals

$6.60

-0.06 (-0.90%)

07:10
12/14/18
12/14
07:10
12/14/18
07:10
Hot Stocks
Idera Pharmaceuticals presents data from Phase 2 expansion of ILUMMINATE-204 »

Idera Pharmaceuticals has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

RBA

Ritchie Bros.

$32.39

-0.28 (-0.86%)

07:08
12/14/18
12/14
07:08
12/14/18
07:08
Hot Stocks
Ritchie Bros. sells C$639M+ of equipment in Edmonton auction »

Ritchie Bros. held its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.90

0.8 (1.21%)

07:07
12/14/18
12/14
07:07
12/14/18
07:07
Recommendations
Starbucks analyst commentary  »

Starbucks story regaining…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

VLKAY

Volkswagen

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

07:07
12/14/18
12/14
07:07
12/14/18
07:07
Hot Stocks
EU passenger car registrations down 8.0% in November »

In November, passenger…

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$120.89

-1.04 (-0.85%)

F

Ford

$8.50

-0.135 (-1.56%)

HMC

Honda

$27.23

-0.03 (-0.11%)

GM

General Motors

$35.11

-0.58 (-1.63%)

FCAU

Fiat Chrysler

$15.67

-0.18 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

CPRX

Catalyst Pharmaceuticals

$2.47

0.075 (3.14%)

07:06
12/14/18
12/14
07:06
12/14/18
07:06
Recommendations
Catalyst Pharmaceuticals analyst commentary  »

Catalyst Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REXR

Rexford Industrial

$31.42

0.09 (0.29%)

07:06
12/14/18
12/14
07:06
12/14/18
07:06
Hot Stocks
Rexford Industrial acquires industrial property for $18.2M »

Rexford Industrial Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COST

Costco

$226.41

-1.41 (-0.62%)

07:05
12/14/18
12/14
07:05
12/14/18
07:05
Recommendations
Costco analyst commentary  »

Costco price target cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:05
12/14/18
12/14
07:05
12/14/18
07:05
General news
Futures lower after underwhelming Chinese data »

Stock futures are…

LPTX

Leap Therapeutics

$2.85

-0.27 (-8.65%)

07:04
12/14/18
12/14
07:04
12/14/18
07:04
Hot Stocks
Leap Therapeutics presents final data from the Phase I/II study of DKN-01 »

Leap provided the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$34.90

2.765 (8.60%)

07:04
12/14/18
12/14
07:04
12/14/18
07:04
Recommendations
Ciena analyst commentary  »

Ciena price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTX

Leap Therapeutics

$2.85

-0.27 (-8.65%)

07:03
12/14/18
12/14
07:03
12/14/18
07:03
Hot Stocks
Leap Therapeutics presents TRX518 data at ESMO »

Leap Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$139.16

-4.28 (-2.98%)

07:03
12/14/18
12/14
07:03
12/14/18
07:03
Recommendations
Trade Desk analyst commentary  »

Trade Desk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCEI

Bonanza Creek

$25.01

-0.26 (-1.03%)

07:02
12/14/18
12/14
07:02
12/14/18
07:02
Initiation
Bonanza Creek initiated  »

Bonanza Creek initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.90

0.8 (1.21%)

07:00
12/14/18
12/14
07:00
12/14/18
07:00
Recommendations
Starbucks analyst commentary  »

Starbucks can sustain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

07:00
12/14/18
12/14
07:00
12/14/18
07:00
General news
FX Update: The dollar has traded firmer »

FX Update: The dollar has…

TCBI

Texas Capital

$53.03

-2.42 (-4.36%)

06:57
12/14/18
12/14
06:57
12/14/18
06:57
Initiation
Texas Capital initiated  »

Texas Capital initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.